Clinical Trials · NCT02384122

Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

CompletedPhase 3Octreotide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Radboud University Medical Center
Enrollment
62
Start date
Sep 2015
Locations
12 sites, Netherlands
Primary endpoint
Difference in blood and parenteral iron requirements (transfusion units)
View Octreotide compound reference